Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OnKure Therapeutics, Inc. (OKUR : NSDQ)

• Company Description    OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $4.21 Daily Weekly Monthly 20 Day Moving Average: 153,724 shares Shares Outstanding: 40.40 (millions) Market Capitalization: $170.06 (millions) Beta: 0.36 52 Week High: $5.38 52 Week Low: $1.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.08% -18.28% 12 Week 58.27% 46.31% Year To Date 45.17% 29.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6707 Winchester Circle Suite 400 - Boulder,CO 80301 USA ph: 720-307-2892 fax: - daniel@lifesciadvisors.com https://onkuretherapeutics.com

• General Corporate Information    Officers Nicholas A. Saccomano - President and Chief Executive Officer Jason Leverone - Chief Financial Officer Isaac Manke - Director R. Michael Carruthers - Director Andrew Phillips - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68277Q105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 40.40 Most Recent Split Date: 10.00 (0.10:1) Beta: 0.36 Market Capitalization: $170.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 6.72% vs. Previous Quarter: -12.12% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -61.02 12/31/25 - -81.69 09/30/25 - -74.86 ROA 03/31/26 - -55.99 12/31/25 - -74.19 09/30/25 - -67.92 Current Ratio 03/31/26 - 13.78 12/31/25 - 10.27 09/30/25 - 11.45 Quick Ratio 03/31/26 - 13.78 12/31/25 - 10.28 09/30/25 - 11.45 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.56 12/31/25 - 4.11 09/30/25 - 4.90 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©